Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
― Appointed Alex C. Sapir CEO & President, effective July 1st, 2023 ― ― On track to complete enrollment in Phase 3 REACH trial of losmapimod in facioscapulohumeral... | May 15, 2023
Source: marketscreener.com